• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Artiva Biotherapeutics, Inc. - Common Stock (NQ:ARTV)

6.830 +0.040 (+0.59%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 587,650
Open 6.890
Bid (Size) 6.690 (100)
Ask (Size) 7.140 (100)
Prev. Close 6.790
Today's Range 6.740 - 7.000
52wk Range 2.710 - 14.53
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026
October 02, 2026
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026)
October 01, 2026
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire

Performance

52-Week Range 53.0% below 52-week high
6.830
2.7152W Low 14.5352W High
1 Week 7.7% below 1-week high
6.741W Low 7.401W High

Artiva Biotherapeutics, Inc. - Common Stock (ARTV) traded between $2.71 and $14.53 over the past 52 weeks and last traded at $6.83, 53.0% below its 52-week high. Over the past week it ranged between $6.74 and $7.40.

Past 12 Months
-3.1%
-38.6%
-27.6%
-6.3%
+61.5%
+131.5%
1W -$0.22
1M -$4.29
3M -$2.61
6M -$0.46
YTD +$2.60
1Y +$3.88

ARTV was +131.5% over the past year, -6.3% over six months, +61.5% year to date, -3.1% in the last week.

12 Months vs Market
ARTV
+131.5%
DIA
+9.3%
SPY
+15.0%
QQQ
+24.3%
IWM
+14.5%

Over the past 12 months ARTV returned +131.5% versus DIA (Dow) +9.3%, SPY (S&P 500) +15.0%, QQQ (Nasdaq 100) +24.3% and IWM (Russell 2000) +14.5%.

Volume & Liquidity 1.45× 3-mo avg
Today 587,650 3-mo avg 405.1K
1W
460.8K
1M
502.7K
3M
405.1K
6M
495.8K
YTD
391.5K
1Y
1.0M

ARTV most recently traded 587,650 shares against a 3-month average daily volume of 405.1K.

More News

Read More
News headline image
Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s Disease
September 23, 2026
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
September 17, 2026
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026
September 08, 2026
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September
September 02, 2026
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 06, 2026
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 17, 2026
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
June 23, 2026
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today
June 08, 2026
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
May 28, 2026
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases
May 19, 2026
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development
May 19, 2026
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
May 14, 2026
Via FinancialNewsMedia
News headline image
Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
May 08, 2026
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 08, 2026
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026
May 08, 2026
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
March 10, 2026
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
February 25, 2026
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant
February 24, 2026
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors
February 19, 2026
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability
January 21, 2026
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Keep an eye on the top gainers and losers in Tuesday's session. ↗
December 16, 2025
Via Chartmill
News headline image
These stocks are moving in today's session ↗
December 16, 2025
Via Chartmill
News headline image
Which stocks are moving on Monday? ↗
December 15, 2025
Via Chartmill

Frequently Asked Questions

Is Artiva Biotherapeutics, Inc. - Common Stock publicly traded?
Yes, Artiva Biotherapeutics, Inc. - Common Stock is publicly traded.
What exchange does Artiva Biotherapeutics, Inc. - Common Stock trade on?
Artiva Biotherapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Artiva Biotherapeutics, Inc. - Common Stock?
The ticker symbol for Artiva Biotherapeutics, Inc. - Common Stock is ARTV on the Nasdaq Stock Market
What is the current price of Artiva Biotherapeutics, Inc. - Common Stock?
The current price of Artiva Biotherapeutics, Inc. - Common Stock is 6.830
When was Artiva Biotherapeutics, Inc. - Common Stock last traded?
The last trade of Artiva Biotherapeutics, Inc. - Common Stock was at 10/02/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap